Relapse and Prognosis of Non-Muscle Invasive Bladder Cancer After Combined HOLRBT with Sunitinib and TGC Perfusion Chemotherapy.

Songjiang Li,Kai Zhao,Yueli Jin,Zheng Ma,Rong Sun,Wei Zhao,Huilei Yan,Yuqiao Li

Relapse and Prognosis of Non-Muscle Invasive Bladder Cancer After Combined HOLRBT with Sunitinib and TGC Perfusion Chemotherapy.

2020

Songjiang Li
Kai Zhao
Yueli Jin
Zheng Ma
Rong Sun
Wei Zhao
Huilei Yan
Yuqiao Li

Objective: To prevent postoperative relapse after HOLRBT, we compared postoperative adjuvant therapies. Methods: One hundred fifty patients with non-muscle invasive bladder cancer (NMIBC) were mean...

Keywords:

Adjuvant
Perfusion
Oncology
Internal medicine
non muscle invasive
One Hundred Fifty
Immunology
Bladder cancer
Chemotherapy
Medicine
Sunitinib

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations